Daniela Latorre1†
Silvia Monticelli2†
Tomasz P. Wypych3†
Dominik Aschenbrenner4†
Samuele Notarbartolo5*†- 1Institute of Microbiology, ETH Zurich, Zurich, Switzerland
- 2Institute for Research in Biomedicine, Università della Svizzera italiana (USI), Bellinzona, Switzerland
- 3Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Poland
- 4Immunology Disease Area, Novartis BioMedical Research, Basel, Switzerland
- 5Infectious Diseases Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
Editorial on the Research Topic
T cell specificity and cross-reactivity – implications in physiology and pathology
T cells are pivotal in orchestrating adaptive immune responses against a myriad of threats. Their ability to recognize antigens presented by specialized antigen-presenting cells (APCs), discern between self and non-self, and regulate and execute tailored immune responses lies at the heart of our immunological defenses. At the forefront of T cell function is the T cell receptor (TCR), a complex molecular machinery tasked with the daunting challenge of discriminating between an extensive array of antigens. Conventional CD8+ and CD4+ T cells recognize antigens exposed by APCs in the form of short peptides loaded onto major histocompatibility complex (MHC) class I and class II molecules, through their TCR (1). This interaction is key for T cell immune function as it triggers a signaling cascade that results in T cell activation, differentiation, and effector response.
The specificity of T cell-mediated immune responses is driven by the diversification of TCRs. TCRs are heterodimers of alpha and beta chains (αβTCR), which are encoded by genes on human chromosome 14 and chromosome 7, respectively. Both loci contain variable (V), joining (J), and constant (C) gene fragments, while only the TCR β locus includes two diversity (D) gene fragments between V and J. TCR diversity is determined at three different levels: the recombination of the V(D)J gene fragments, the generation of random junctional sequences by the terminal deoxynucleotidyl transferase enzyme, and the pairing of the productive alpha and beta chains. The theoretical repertoire of human T cells is enormous [possibly 1019-1020 (2, 3)], with the sole V(D)J recombination contributing with more than 5 × 106 possible combinations of TCR gene fragments, assuming these are all equally possible (Table 1). However, 108-1010 is the estimated number of unique TCRs surviving clonal (positive and negative) selection in the thymus and forming the mature T cell repertoire (5–7). These numbers are several orders of magnitude lower than the possible array of peptides that can be generated and accommodated into an MHC molecule (8). Considering the disparity between the number of possible foreign antigens and TCRs, the “one-clonotype–one-specificity” paradigm would result in a breach of the adaptive immune barrier.
Table 1 TCR diversity based on V(D)J recombination and αβ chains pairing.
This deficit in TCR diversity is resolved by T cell cross-reactivity, that is the ability of a single TCR to bind multiple peptide-MHC complexes, albeit with different affinities. In addition to the theoretical need, numerous independent studies have experimentally demonstrated the existence of cross-reactive T cells [reviewed in (9, 10)].
In this Research Topic, we aim to offer an overview of established knowledge and recent advances in the field of T cell cross-reactivity, providing novel insights into the processes governing this phenomenon.
First, Acuto comprehensively analyzes the mechanisms regulating TCR activation and signaling portraying the context of T cell reactivity and cross-reactivity. He reviews the role of MHC-I and MHC-II, TCR αβ, and the uncertainties in understanding how peptide-MHC binding induces TCR signals. Next, he discusses various models of TCR activation, such as oligomerization, mechanotransduction, and allosteric activation, including recent evidence suggesting that TCR-CD3 activation may be controlled by an allosteric mechanism requiring only monomeric peptide-MHC binding. Finally, he proposes a unifying model for TCR activation.
TCR signaling is key for T cell activation in the periphery and governs T cell clonal selection in the thymus. Thymic selection shapes the mature T cell repertoire by eliminating non-reactive or strongly self-reactive T cell clones and directing the differentiation of conventional naïve and regulatory T (Treg) cells. Welsh et al. show that H2-O, an MHC-II peptide editing molecular chaperon, limits Treg cell differentiation in the thymus and CD4+ T cell hyperactivity in the periphery, possibly by modulating the range of peptides with different affinities presented on MHC-II during the thymic selection.
Still in the context of modulating TCR responses, Balasubramanian and Sundrud review the role of ATP-binding cassette (ABC) transporters in immune regulation, specifically focusing on MDR1. ABC transporters are increasingly recognized for their involvement in T cell development and function. MDR1, in particular, contributes to T cell antioxidant function, influencing TCR signaling, metabolic pathways, and oxidative stress responses. The authors discuss how MDR1 may be central to shaping the magnitude, type, and even the repertoire of T cells during antigen-specific responses and highlight the potential of ABC transporters as targets to improve therapeutic immune responses.
Cross-reactivity has evolved to cope with the enormous diversity of mutating pathogens. T cell cross-reactivity facilitates polyclonal immune responses to a single antigen and increases resistance to escape mutants. It can also induce heterologous immunity, that is the generation of memory to a pathogen different from the one against which the immune response has been originally raised. These concepts have become evident in the recent SARS-CoV-2 infection pandemics (11). Westphal et al. bring new evidence to this topic, demonstrating that CD4+ T cells responding to the nonstructural protein 12 (NSP12) of SARS-CoV-2 can be found both in COVID-19 patients and seronegative individuals and cross-react with the homologous protein of common-cold coronaviruses. Interestingly, they observed that NSP12 immunodominant epitopes are recognized by CD4+ T cells with different frequencies in COVID-19 patients and seronegative individuals and that the frequency of the response does not necessarily correlate with the NSP12 sequence conservation in different coronavirus species. These data suggest that epitope similarity is only one of the drivers of T cell cross-reactivity.
A deeper understanding of the principles underlying T cell cross-reactivity may also have implications for therapeutic applications. For instance, Bodas-Pinedo et al. explore the cross-reactivity between bacteria and viruses as a tool for designing better vaccines. Using an in-silico approach, they analyzed shared peptidome spaces and cross-reactive T cells between a selected bacterial consortium and the Influenza A virus and identified cross-reactivity patterns between bacterial and viral epitopes that might be harnessed to design better vaccines against flu.
Besides, using data from peptide:MHC-I and pMHC:TCR structures, Papadaki et al. identified residues important for MHC-I binding to peptides and TCR. Then, they developed a computational platform to design synthetic HLA molecules that could be used as screening tools to evaluate peptide-centric interactions with TCRs, such as for the development of improved chimeric antigen receptors (CARs).
Nonetheless, T cell cross-reactivity is a double-edged sword and can have both positive and negative consequences. Gouttefangeas et al. describe the dilemma faced by T cells that need to achieve both optimal target specificity and complete coverage of the complex spectrum of foreign antigens while avoiding reactivity to self-derived peptides. They provide an overview of the basic mechanisms underlying T cell cross-reactivity and comprehensively review its main detrimental consequence, namely the recognition of self-antigens causing autoimmunity. They also highlight a less frequently appreciated positive aspect of cross-reactivity, namely enabling T cells to recognize tumor-associated antigens.
On the same line, Thomas and Olsson focus on the role of molecular mimicry and cross-reactive T cells in the pathogenesis of multiple sclerosis (MS). They delve into the current knowledge of the intricate autoantigen repertoire targeted by autoreactive T cells in MS, detailing the evidence of cross-reactivity between antigens derived from Epstein-Barr virus (but also other microbes) and autoantigens in the host’s central nervous system (CNS). These data highlight the urgent need for further research to fully understand the role of foreign antigens in the development and progression of CNS demyelinating diseases.
Finally, Carbone et al. investigate immune-related adverse events (irAEs) in oncologic patients undergoing immunotherapy, focusing on cases of vitiligo onset in melanoma patients receiving therapeutic anti-PD-1. They show that T cells in patients with spontaneous and immunotherapy-associated vitiligo had a different immune profile, suggesting a different etiopathology of the two autoimmune clinical manifestations. Moreover, using TCR-sequencing, they find shared T cell clones in vitiligo skin lesions and metastatic (but not primary) melanoma biopsies, suggesting that an immune response against metastatic cells may trigger vitiligo development. Considering that irAEs are the main cause of immunotherapy discontinuation, increasing our understanding of the cross-reactivity of T cells to tumor-associated and self-antigens will be instrumental in developing innovative immunotherapies with limited irAEs.
In conclusion, despite all the acquired knowledge, a lot remains to be learned about cross-reactive T cells, such as phenotype and function in health and disease, TCR repertoires, and target antigens. A deeper understanding of the processes and principles associated with T cell activation, specificity, and cross-reactivity will have relevant implications in the prevention and treatment of autoimmune diseases, the development of vaccines, the optimization of engineered TCRs targeting tumor antigens, and the advancement of innovative approaches for precision medicine.
Author contributions
SN: Conceptualization, Writing – original draft, Writing – review & editing. DL: Writing – review & editing. SM: Writing – review & editing. TW: Writing – review & editing. DA: Writing – review & editing.
Funding
The author(s) declare financial support was received for the research, authorship, and/or publication of this article. SN is supported by a Ricerca Finalizzata Giovani Ricercatori grant from the Italian Ministry of Health (RF GR-2021-12374097). DL work on this topic is supported by the Swiss National Science Foundation PRIMA grant (PR00P3_185742), the Elevation Research Grant from the GBS/CIDP Foundation International and the Novartis Foundation for medical-biological Research. Work in the SM lab on this topic is funded by the Swiss National Science Foundation Excellence grant number 310030_205197. TW is supported by the National Science Centre, grants number 2020/39/D/NZ6/02146 and 2021/41/B/NZ6/02219.
Conflict of interest
Author DA is employed by Novartis Pharma AG and a shareholder of Novartis Pharma AG.
The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Davis MM, Boniface JJ, Reich Z, Lyons D, Hampl J, Arden B, et al. Ligand recognition by alpha beta T cell receptors. Annu Rev Immunol. (1998) 16:523–44. doi: 10.1146/annurev.immunol.16.1.523
2. Zarnitsyna VI, Evavold BD, Schoettle LN, Blattman JN, Antia R. Estimating the diversity, completeness, and cross-reactivity of the T cell repertoire. Front Immunol. (2013) 4:485. doi: 10.3389/fimmu.2013.00485
3. Dupic T, Marcou Q, Walczak AM, Mora T. Genesis of the alphabeta T-cell receptor. PloS Comput Biol. (2019) 15:e1006874. doi: 10.1371/journal.pcbi.1006874
4. Corcoran M, Chernyshev M, Mandolesi M, Narang S, Kaduk M, Ye K, et al. Archaic humans have contributed to large-scale variation in modern human T cell receptor genes. Immunity. (2023) 56:635–652.e6. doi: 10.1016/j.immuni.2023.01.026
5. Britanova OV, Putintseva EV, Shugay M, Merzlyak EM, Turchaninova MA, Staroverov DB, et al. Age-related decrease in TCR repertoire diversity measured with deep and normalized sequence profiling. J Immunol. (2014) 192:2689–98. doi: 10.4049/jimmunol.1302064
6. Qi Q, Liu Y, Cheng Y, Glanville J, Zhang D, Lee JY, et al. Diversity and clonal selection in the human T-cell repertoire. Proc Natl Acad Sci USA. (2014) 111:13139–44. doi: 10.1073/pnas.1409155111
7. Sun X, Nguyen T, Achour A, Ko A, Cifello J, Ling C, et al. Longitudinal analysis reveals age-related changes in the T cell receptor repertoire of human T cell subsets. J Clin Invest. (2022). 1;132(17):e158122 doi: 10.1172/JCI158122
8. Sewell AK. Why must T cells be cross-reactive? Nat Rev Immunol. (2012) 12:669–77. doi: 10.1038/nri3279
9. Petrova G, Ferrante A, Gorski J. Cross-reactivity of T cells and its role in the immune system. Crit Rev Immunol. (2012) 32:349–72. doi: 10.1615/CritRevImmunol.v32.i4.50
10. Jiang N, Malone M, Chizari S. Antigen-specific and cross-reactive T cells in protection and disease. Immunol Rev. (2023) 316:120–35. doi: 10.1111/imr.13217
Keywords: cross-reactive T cells, T cell cross-reactivity, T cell receptor (TCR), molecular mimicry, T cell repertoire, autoimmune diseases, heterologous immunity and protection, evolution of T cell immunity
Citation: Latorre D, Monticelli S, Wypych TP, Aschenbrenner D and Notarbartolo S (2024) Editorial: T cell specificity and cross-reactivity – implications in physiology and pathology. Front. Immunol. 15:1385415. doi: 10.3389/fimmu.2024.1385415
Received: 12 February 2024; Accepted: 19 February 2024;
Published: 28 February 2024.
Edited and Reviewed by:
Mariolina Salio, Immunocore, United KingdomCopyright © 2024 Latorre, Monticelli, Wypych, Aschenbrenner and Notarbartolo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Samuele Notarbartolo, samuele.notarbartolo@policlinico.mi.it
†These authors have contributed equally to this work